# EDGAR Filing Document

**Accession Number:** 0000822663
**File Stem:** 0001753926-25-001703
**Filing Date:** 2025-11
**Character Count:** 107003
**Document Hash:** 8f5e897ca2b81d352bcf93df18065731
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001753926-25-001703.hdr.sgml**: 20251105

**ACCESSION NUMBER**: 0001753926-25-001703

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 53

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251105

**DATE AS OF CHANGE**: 20251105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INTERPARFUMS INC
- **CENTRAL INDEX KEY:** 0000822663
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133275609
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-16469
- **FILM NUMBER:** 251454471

**BUSINESS ADDRESS:**
- **STREET 1:** 551 FIFTH AVE
- **STREET 2:** STE 1500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10176
- **BUSINESS PHONE:** 2129832640

**MAIL ADDRESS:**
- **STREET 1:** 551 FIFTH AVENUE
- **STREET 2:** STE 1500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10176

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTER PARFUMS INC
- **DATE OF NAME CHANGE:** 19990715

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JEAN PHILIPPE FRAGRANCES INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? ipar-20250930.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

**(MARK ONE)**

**☒** Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2025.

**OR**

☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ___________to ________.

Commission File No. **<u>0-16469</u>**

***INTERPARFUMS, INC.***

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **13-3275609** |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |

---

---

| |
|:---|
| **551 Fifth Avenue, New York, New York 10176** |
| (Address of Principal Executive Offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Zip Code) |

---

---

| |
|:---|
| **(212) 983-2640** |
| (Registrants telephone number, including area code) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $.001 par value per share | IPAR | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes **☒** No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes **☒** No **☐**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act).

---

| | |
|:---|:---|
| &nbsp;&nbsp;Large accelerated filer ☒ | &nbsp;&nbsp;Accelerated filer ☐ |
| &nbsp;&nbsp;Non-accelerated filer ☐ (Do not check if a smaller reporting company) | &nbsp;&nbsp;Smaller reporting company ☐ |
|  | &nbsp;&nbsp;Emerging Growth company ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes **☐** No **☒**

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

At November 5, 2025, there were 32,064,728 shares of common stock, par value $.001 per share, outstanding.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**INDEX**

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | Page Number  |
| [Part I.](#BRN1_1462024194129560) | [Financial Information](#BRN1_1462024194129560) | [Financial Information](#BRN1_1462024194129560) | 1 |
|  | [Item 1.](#BRN2_146202419426753) | [Financial Statements](#BRN2_146202419426753) | 1 |
|  |  | [Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024](#BRN3_146202419434645) | 2 |
|  |  | [Consolidated Statements of Income for the Three and Nine Months Ended September 30, 2025 and September 30, 2024](#BRN4_1462024194330786) | 3 |
|  |  | [Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and September 30, 2024](#BRN5_1462024194414665) | 4 |
|  |  | [Consolidated Statements of Changes in Equity for the Three and Nine Months Ended September 30, 2025 and September 30, 2024](#BRN6_1462024194556690) | 5 |
|  |  | [Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and September 30, 2024](#BRN7_1462024194633562) | 6 |
|  |  | [Notes to Consolidated Financial Statements](#BRN8_1462024194735586) | 7 |
|  | [Item 2.](#BBRN9_272024114355882) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#BBRN9_272024114355882) | 17 |
|  | [Item 3.](#BRN10_146202419492549) | [Quantitative and Qualitative Disclosures About Market Risk](#BRN10_146202419492549) | 17 |
|  | [Item 4.](#BRN11_1462024194913564) | [Controls and Procedures](#BRN11_1462024194913564) | 17 |
| [Part II.](#BRN12_146202419494757) | [Other Information](#BRN12_146202419494757) | [Other Information](#BRN12_146202419494757) | 26 |
|  | [Item 1A.](#BItem_1A_41020251333367) | [Risk Factors](#BItem_1A_41020251333367) | 26 |
|  | [Item 2.](#BRN13_146202419501178) | [Unregistered Sales of Equity Securities and Use of Proceeds.](#BRN13_146202419501178) | 26 |
|  | [Item 5.](#BRN14_1462024195015817) | [Other Information](#BRN14_1462024195015817) | 26 |
|  | [Item 6.](#BRN15_1462024195037528) | [Exhibits.](#BRN15_1462024195037528) | 27 |
| [SIGNATURES](#BRN16_146202419513640) | [SIGNATURES](#BRN16_146202419513640) | [SIGNATURES](#BRN16_146202419513640) | 28 |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[**Part I. Financial Information**](#TOC)

---

| | |
|:---|:---|
| **Item** **1.** | [**Financial Statements**](#TOC) |

---

In our opinion, the accompanying unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to present fairly our financial position, results of operations and cash flows for the interim periods presented. We have condensed such financial statements in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC"). Therefore, such financial statements do not include all disclosures required by accounting principles generally accepted in the United States of America. In preparing these consolidated financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through the date the consolidated financial statements were issued by filing with the SEC. These financial statements should be read in conjunction with our audited financial statements for the year ended December 31, 2024, included in our annual report filed on Form 10-K.

The results of operations for the nine months ended September 30, 2025, are not necessarily indicative of the results to be expected for the entire fiscal year.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**[CONSOLIDATED BALANCE SHEETS](#TOC)**

(In thousands except share and per share data)

 *(Unaudited)*

---

| | | |
|:---|:---|:---|
| ***ASSETS*** |  |  |
|  | **September 30, 2025** | **December 31, 2024** |
| **Current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $110396 | $125433 |
| &nbsp;&nbsp;&nbsp;Short-term investments | 77460 | 109311 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 363624 | 274705 |
| &nbsp;&nbsp;&nbsp;Inventories | 388302 | 371920 |
| &nbsp;&nbsp;&nbsp;Receivables, other | 10369 | 6122 |
| &nbsp;&nbsp;&nbsp;Other current assets | 40587 | 27035 |
| &nbsp;&nbsp;&nbsp;Income taxes receivable |  | 306 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 990738 | 914832 |
| **Property, equipment and leasehold improvements, net** | 186206 | 153773 |
| **Right-of-use assets, net** | 24558 | 24603 |
| **Trademarks, licenses and other intangible assets, net** | 328220 | 282484 |
| **Deferred tax assets** | 15262 | 17034 |
| **Other assets** | 19666 | 18535 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $1564650 | $1411261 |
| ***LIABILITIES AND EQUITY*** |  |  |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Loans payable - banks | $9393 | $8311 |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debt | 56901 | 41607 |
| &nbsp;&nbsp;&nbsp;Current portion of lease liabilities | 6193 | 6087 |
| &nbsp;&nbsp;&nbsp;Accounts payable – trade | 66985 | 91049 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 152624 | 172758 |
| &nbsp;&nbsp;&nbsp;Income taxes payable | 10677 | 12615 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 302773 | 332427 |
| **Long–term debt, less current portion** | 139976 | 115734 |
| **Lease liabilities, less current portion** | 17406 | 20455 |
| **Equity:** |  |  |
| &nbsp;&nbsp;&nbsp;Interparfums, Inc. shareholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $.001 par; authorized 1,000,000 shares; none issued |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $.001 par; authorized 100,000,000 shares; outstanding 32,064,728 and 32,110,170 shares at September 30, 2025 and December 31, 2024, respectively | 32 | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 109006 | 106702 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 826964 | 763240 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (4780) | (72239) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, at cost, 8,960,587 and 9,981,665 shares at September 30, 2025 and December 31, 2024, respectively | (60335) | (52864) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Interparfums, Inc. shareholders' equity | 870887 | 744871 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interest | 233608 | 197774 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 1104495 | 942645 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and equity** | $1564650 | $1411261 |

---

*See notes to consolidated financial statements.*

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[***CONSOLIDATED STATEMENTS OF INCOME***](#TOC)

(In thousands except per share data)

 *(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Net sales** | $429579 | $424629 | $1102334 | $1090821 |
| **Cost of sales** | 156762 | 153469 | 392451 | 396519 |
| **Gross margin** | 272817 | 271160 | 709883 | 694302 |
| **Selling, general and administrative expenses** | 164261 | 165166 | 467074 | 455506 |
| **Income from operations** | 108556 | 105994 | 242809 | 238796 |
| **Other expenses (income):** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | 2305 | 1978 | 5637 | 5726 |
| &nbsp;&nbsp;&nbsp;Loss on foreign currency | 2215 | 3355 | 4576 | 3085 |
| &nbsp;&nbsp;&nbsp;Interest and investment (income) loss | (2547) | 254 | (1199) | (1690) |
| &nbsp;&nbsp;&nbsp;Other (income) loss | (978) | 1 | (1302) | (35) |
| **Nonoperating Income (Expense)** | 995 | 5588 | 7712 | 7086 |
| **Income before income taxes** | 107561 | 100406 | 235097 | 231710 |
| Income taxes | 24282 | 23571 | 55218 | 54974 |
| **Net income** | 83279 | 76835 | 179879 | 176736 |
| &nbsp;&nbsp;&nbsp;Less: Net income attributable to the noncontrolling interest | 17470 | 14576 | 39590 | 36606 |
| **Net income attributable to Interparfums, Inc.** | $65809 | $62259 | $140289 | $140130 |
| **Earnings per share:** |  |  |  |  |
| **Net income attributable to Interparfums, Inc. common shareholders:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | $2.05 | $1.94 | $4.37 | $4.37 |
| &nbsp;&nbsp;&nbsp;Diluted | $2.05 | $1.93 | $4.36 | $4.34 |
| **Weighted average number of shares outstanding:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 32113 | 32026 | 32114 | 32030 |
| &nbsp;&nbsp;&nbsp;Diluted | 32149 | 32266 | 32158 | 32266 |
| **Dividends declared per share** | $0.80 | $0.75 | $2.40 | $2.25 |

---

*See notes to consolidated financial statements.*

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[***CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME***](#TOC)

(In thousands)

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Comprehensive income:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net income | $83279 | $76835 | $179879 | $176736 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net derivative instrument (loss) gain, net of tax | (5540) | (239) | 965 | (1411) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer from OCI into earnings |  |  | 1631 | (64) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension benefits, net of tax | (51) |  | (153) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Translation adjustments, net of tax | 834 | 31385 | 87936 | 10891 |
| **Comprehensive income** | 78522 | 107981 | 270258 | 186152 |
| **Comprehensive income attributable to the noncontrolling interests:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net income | 17470 | 14576 | 39590 | 36606 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net derivative instrument (loss) gain, net of tax | (1522) | (66) | 271 | (388) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension benefits, net of tax | (14) |  | (43) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Translation adjustments, net of tax | (40) | 8989 | 22692 | 2257 |
| **Comprehensive income attributable to the noncontrolling interests** | 15894 | 23499 | 62510 | 38475 |
| **Comprehensive income attributable to Interparfums, Inc.** | $62628 | $84482 | $207748 | $147677 |

---

*See notes to consolidated financial statements.*

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[***CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY***](#TOC)

(In thousands)

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Common stock, beginning and end of period** | $32 | $32 | $32 | $32 |
| **Additional paid-in capital, beginning of period** | 108802 | 100505 | 106702 | 98565 |
| &nbsp;&nbsp;&nbsp;Shares issued upon exercise of stock options |  | 359 | 2112 | 1729 |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 204 | 259 | 615 | 780 |
| &nbsp;&nbsp;&nbsp;Purchase/Transfer of subsidiary shares |  |  | (423) | 49 |
| **Additional paid-in capital, end of period** | 109006 | 101123 | 109006 | 101123 |
| **Retained earnings, beginning of period** | 787031 | 724268 | 763240 | 693848 |
| &nbsp;&nbsp;&nbsp;Net income | 65809 | 62259 | 140289 | 140130 |
| &nbsp;&nbsp;&nbsp;Dividends | (25695) | (24022) | (77089) | (71985) |
| &nbsp;&nbsp;&nbsp;Share-based compensation | (181) | 321 | 524 | 833 |
| **Retained earnings, end of period** | 826964 | 762826 | 826964 | 762826 |
| **Accumulated other comprehensive loss, beginning of period** | (1599) | (54864) | (72239) | (40188) |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustment, net of tax | 874 | 22396 | 65244 | 8634 |
| &nbsp;&nbsp;&nbsp;Transfer from other comprehensive income into earnings |  |  | 1631 | (64) |
| &nbsp;&nbsp;&nbsp;Pension benefits, net of tax | (37) |  | (110) |  |
| &nbsp;&nbsp;&nbsp;Net derivative instrument gain (loss), net of tax | (4018) | (173) | 694 | (1023) |
| **Accumulated other comprehensive loss, end of period** | (4780) | (32641) | (4780) | (32641) |
| **Treasury stock, beginning of period** | (54907) | (52864) | (52864) | (52864) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares repurchased | (5428) |  | (7471) |  |
| **Treasury stock, end of period** | (60335) | (52864) | (60335) | (52864) |
| **Noncontrolling interest, beginning of period** | 217393 | 184129 | 197774 | 192777 |
| &nbsp;&nbsp;&nbsp;Net income | 17470 | 14576 | 39590 | 36606 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustment, net of tax | (40) | 8989 | 22692 | 2257 |
| &nbsp;&nbsp;&nbsp;Pension benefits, net of tax | (14) |  | (43) |  |
| &nbsp;&nbsp;&nbsp;Net derivative instrument gain (loss), net of tax | (1522) | (66) | 271 | (388) |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 321 | 47 | 199 | 179 |
| &nbsp;&nbsp;&nbsp;Transfer of subsidiary shares purchased |  |  |  | (49) |
| &nbsp;&nbsp;&nbsp;Dividends |  | (1022) | (26875) | (24729) |
| **Noncontrolling interest, end of period** | 233608 | 206653 | 233608 | 206653 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total equity** | $1104495 | $985129 | $1104495 | $985129 |

---

*See notes to consolidated financial statements.*

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[***CONSOLIDATED STATEMENTS OF CASH FLOWS***](#TOC)

(In thousands)

*(Unaudited)*

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 30,** | **September 30,** |
|  | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Net income | $179879 | $176736 |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 18836 | 18201 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for doubtful accounts | 1716 | 613 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncash stock compensation | 1313 | 1768 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share of income of equity investment | (673) | (109) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncash lease expense | 4809 | 4533 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax provision | 3454 | (4909) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivatives | (7064) | (153) |
| &nbsp;&nbsp;&nbsp;Changes in: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (62901) | (102576) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 18749 | (35237) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | (4035) | 3770 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (5037) | (4378) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | (77469) | (17571) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes, net | (3204) | 8993 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 68373 | 49681 |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of short-term investments | (93244) | (146868) |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of short-term investments | 137150 | 162176 |
| &nbsp;&nbsp;&nbsp;Purchases of property, equipment and leasehold improvements | (22866) | (2889) |
| &nbsp;&nbsp;&nbsp;Payment for intangible assets acquired | (22882) | (850) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by investing activities | (1842) | 11569 |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from loans payable, bank |  | 4348 |
| &nbsp;&nbsp;&nbsp;Proceeds of issuance of long-term debt | 55940 | 43484 |
| &nbsp;&nbsp;&nbsp;Repayment of long-term debt | (37046) | (24781) |
| &nbsp;&nbsp;&nbsp;Proceeds from exercise of options | 2112 | 1729 |
| &nbsp;&nbsp;&nbsp;Dividends paid | (77089) | (71985) |
| &nbsp;&nbsp;&nbsp;Dividends paid to noncontrolling interest | (26875) | (24729) |
| &nbsp;&nbsp;&nbsp;Purchase of subsidiary shares from noncontrolling interests | (423) |  |
| &nbsp;&nbsp;&nbsp;Purchase of treasury stock | (7471) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (90852) | (71934) |
| **Effect of exchange rate changes on cash** | 9284 | 641 |
| **Net decrease in cash and cash equivalents**  | (15037) | (10043) |
| Cash and cash equivalents - beginning of period | 125433 | 88462 |
| **Cash and cash equivalents - end of period** | $110396 | $78419 |
| **Supplemental disclosure of cash flow information:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest | $4993 | $6578 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | 55948 | 48643 |

---

*See notes to consolidated financial statements.* 

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[**Notes to Consolidated Financial Statements**](#TOC)

*(Unaudited)* 

**1.** **<u>Significant Accounting Policies:</u>**

The accounting policies we follow are set forth in the notes to our consolidated financial statements included in our Form 10-K, which was filed with the Securities and Exchange Commission for the year ended December 31, 2024.

**2.** **<u>Recent Agreements:</u>**

***Longchamp***

In July 2025, we announced that our 72% owned French subsidiary, Interparfums SA, signed an exclusive license agreement with Longchamp, a Parisian Maison, through December 31, 2036. Interparfums SA will be responsible for the creation, development, production and distribution of fragrance lines in Longchamp-brand points of sale and selective distribution channels. The first launch is expected in 2027. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry.

***Goutal***

In March 2025, we announced that our 72% owned French subsidiary, Interparfums SA, acquired all intellectual property rights relating to Maison Goutal held by Amorepacific Europe. Amorepacific Europe will continue to operate the Goutal brand under an existing license agreement that expires on December 31, 2025, when Interparfums SA will begin commercial use of the fragrance brand.

***Coach***

**In 2015, Coach and Interparfums SA signed an exclusive worldwide license agreement for the creation, the manufacturing and the distribution of fragrances under the Coach brand until June 30, 2026. In March 2025, the license agreement was renewed for an additional 5-year term, extending the license through June 30, 2031.** 

***Abercrombie & Fitch and Hollister***

In March 2025, we expanded our *Fierce* distribution agreement, which now allows for a global distribution of the iconic *Fierce* fragrance line that either party may terminate on two year's notice. Furthermore, our existing Abercrombie & Fitch and Hollister fragrance license agreement will expire on March 14, 2028. The goal of the updated *Fierce* distribution agreement is to drive, over time, more consistency between the products that are carried in the Abercrombie & Fitch stores and unaffiliated retailers.

***Off-White***

In December 2024, we announced that our 72% owned French subsidiary, Interparfums SA, signed for all Off-White® brand names and registered trademarks for Class 3 fragrance and cosmetic products, subject to an existing license that expires on December 31, 2025, when Interparfums SA will begin commercial use of the fragrance brand.

***Van Cleef & Arpels***

**In 2006, Van Cleef & Arpels and Interparfums SA signed a 12-year worldwide license agreement to manufacture and distribute perfumes and related products under the Van Cleef & Arpels brand name, which was subsequently extended for a further six years until December 31, 2024. In December 2024, the license agreement was renewed for an additional 9-year term, through December 31, 2033.** 

***Roberto Cavalli***

In July 2023, we closed a transaction agreement with Roberto Cavalli, whereby an exclusive and worldwide license was granted for the production and distribution of Roberto Cavalli brand perfumes and fragrance related products. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. The license became effective in July 2023 and will last for 6.5 years. We began shipping Roberto Cavalli perfumes and fragrance related products in February 2024.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

 ***Notes to Consolidated Financial Statements***

***Lacoste***

In December 2022, we closed a transaction agreement with Lacoste, whereby an exclusive and worldwide license was granted for the production and distribution of Lacoste brand perfumes and cosmetics. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. The license became effective in January 2024 and will last for 15 years. We began shipping Lacoste fragrances in January 2024.

***Dunhill***

The Dunhill fragrance license expired on September 30, 2023 and was not renewed. The Company had a twelve-month sell-off period during which it maintained the right to sell-off remaining Dunhill fragrance inventory, which is customary in the fragrance industry. As of September 30, 2024, all finished goods and components have been sold and we no longer carry any inventory related to Dunhill.

***Rochas Fashion***

As a result of operational challenges faced by the Rochas Fashion business, we took a $2.4 million impairment charge on our Rochas fashion trademark in the first quarter of 2021 and a $6.8 million impairment charge in the fourth quarter of 2022 after management reviewed and agreed with an independent expert's conclusion that the fair value of the trademark was $11.2 million. In 2023, the Rochas team underwent a strategic shift to take over their own brand operations, exiting contracts with manufacturers and distributors to make this new structure operational beginning in 2024. In the fourth quarter of 2024, we again took a $4.0 million impairment charge on the Rochas fashion trademark after management reviewed and agreed with an independent expert's conclusion that the fair value of the trademark was $7.2 million. There have been no triggering events through the first three quarters of 2025 that would require management to perform an impairment analysis.

**3.** **<u>Recent Accounting Pronouncements:</u>**

In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses and in January 2025, the FASB issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarified the effective date of ASU 2024-03. The ASU requires, among other things, more detailed disclosures about types of expenses in commonly presented expense captions such as cost of sales and selling, general and administrative expenses and is intended to improve the disclosures about an entity's expenses including purchases of inventory, employee compensation, depreciation and intangible asset amortization. ASU 2024-03 will also require the Company to disclose both the amount and the Company's definition of selling expenses. The guidance, as clarified by ASU 2025-01, is effective for fiscal years beginning after December 15, 2026, and interim periods for fiscal years beginning after December 15, 2027, on a prospective or retrospective basis. Early adoption is permitted. We are currently evaluating the impact of adopting this ASU on our disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU includes amendments requiring enhanced income tax disclosures, primarily related to standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted and shall be applied on a prospective basis with the option to apply retrospectively. We are currently evaluating the impact of adopting this ASU on our disclosures.

There are no other recent accounting pronouncements issued but not yet adopted that would have a material effect on our consolidated financial statements.

**4.** **<u>Inventories:</u>**

Inventories consist of the following:

---

| | | |
|:---|:---|:---|
| (In thousands) | **September 30, 2025** | **December 31, 2024** |
| Raw materials and component parts | $123421 | $137572 |
| Finished goods | 264881 | 234348 |
|  | $388302 | $371920 |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

**5.** **<u>Fair Value Measurement:</u>**

The following tables present our financial assets and liabilities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. The fair value hierarchy has three levels based on the reliability of the inputs used to determine fair value.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | **Fair Value Measurements at September 30, 2025** | **Fair Value Measurements at September 30, 2025** | **Fair Value Measurements at September 30, 2025** |
|  | **Total** | **Quoted Prices in<br> Active Markets for<br> Identical Assets<br> (Level 1)** | **Significant Other<br> Observable<br> Inputs<br> (Level 2)** | **Significant<br> Unobservable<br> Inputs<br> (Level 3)** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;Short-term investments | $77460 | $3579 | $73881 | $— |
| &nbsp;&nbsp;Interest rate swaps | 1603 |  | 1603 |  |
| &nbsp;&nbsp;Foreign currency forward exchange contracts not accounted for using hedge accounting | 6911 |  | 6911 |  |
| &nbsp;&nbsp;Foreign currency forward exchange contracts accounted for using hedge accounting |  |  |  |  |
| &nbsp;&nbsp;Total Assets | $85974 | $3579 | $82395 | $— |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | **Fair Value Measurements at December 31, 2024** | **Fair Value Measurements at December 31, 2024** | **Fair Value Measurements at December 31, 2024** |
|  | **Total** | **Quoted Prices in<br> Active Markets for<br> Identical Assets<br> (Level 1)** | **Significant Other<br> Observable<br> Inputs<br> (Level 2)** | **Significant<br> Unobservable<br> Inputs<br> (Level 3)** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;Short-term investments | $109311 | $7703 | $101608 | $— |
| &nbsp;&nbsp;Interest rate swaps | 1967 |  | 1967 |  |
| &nbsp;&nbsp;Total Assets | $111278 | $7703 | $103575 | $— |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;Foreign currency forward exchange contracts not accounted for using hedge accounting | 445 |  | 445 |  |
| &nbsp;&nbsp;Foreign currency forward exchange contracts accounted for using hedge accounting | 1435 |  | 1435 |  |
| &nbsp;&nbsp;Total Liabilities | $1880 | $— | $1880 | $— |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

The carrying amount of cash and cash equivalents, short-term investments including money market funds and marketable equity securities, accounts receivable, other receivables, accounts payable and accrued expenses approximate fair value due to the short terms to maturity of these instruments. The carrying amount of loans payable approximates fair value as the interest rates on the Company's indebtedness approximate current market rates. The fair value of the Company's long-term debt was estimated based on the current rates offered to companies for debt with the same remaining maturities and is approximately equal to its carrying value.

Foreign currency forward exchange contracts are valued based on quotations from financial institutions and the value of interest rate swaps is the discounted net present value of the swaps using third party quotes from financial institutions.

**6.** **<u>Derivative Financial Instruments:</u>**

The Company enters into foreign currency forward exchange contracts to hedge exposure related to receivables denominated in a foreign currency and occasionally to manage risks related to future sales expected to be denominated in a foreign currency. Before entering into a derivative transaction for hedging purposes, we determine that a high degree of initial effectiveness exists between the change in value of the hedged item and the change in the value of the derivative instrument from movement in exchange rates. High effectiveness means that the change in the cash flows of the derivative instrument will effectively offset the change in the cash flows of the hedged item. The effectiveness of each hedged item is measured throughout the hedged period and is based on the dollar offset methodology and excludes the portion of the fair value of the foreign currency forward exchange contract attributable to the change in spot-forward difference which is reported in current period earnings. Any hedge ineffectiveness is also recognized as a gain or loss on foreign currency in the income statement. For contracts designated as hedges that are no longer deemed highly effective, hedge accounting is discontinued, and gains and losses accumulated in other comprehensive income are reclassified to earnings. If it is probable that the forecasted transaction will no longer occur, then any gains or losses accumulated in other comprehensive income are reclassified to current-period earnings.

In December 2022, to finance the acquisition of the Lacoste trademark, the Company entered into a €50 million (approximately $58.7 million) 4-year term loan with a variable interest rate. This variable rate debt was swapped for variable interest rate debt with a maximum rate of 2% per annum. This swap is a hedged derivative instrument and is therefore recorded at fair value and changes in fair value are reflected in the accompanying consolidated statements of comprehensive income.

In connection with the April 2021 acquisition of the office building complex in Paris, €120 million (approximately $140.9 million) of the purchase price was financed through a 10-year variable rate term loan. The Company entered into interest rate swap contracts related to €80 million of the loan, effectively exchanging the variable interest rate to a fixed rate of approximately 1.1%. This derivative instrument is recorded at fair value and changes in fair value are reflected in the accompanying consolidated statements of income.

Gains and losses in derivatives designated as hedges are accumulated in other comprehensive income and gains and losses in derivatives not designated as hedges are included in loss (gain) on foreign currency in the accompanying consolidated statements of income. Such gains and losses were immaterial for the three and nine months ended September 30, 2025 and 2024, respectively.

All derivative instruments are reported as either assets or liabilities on the consolidated balance sheet measured at fair value. The fair value of interest rate swaps includes a liability position which is included in long-term debt on the accompanying consolidated balance sheet, and an asset position which is included in other assets on the accompanying balance sheet. The fair value of foreign currency forward exchange contracts at September 30, 2025, resulted in a net asset and is included in other current assets on the accompanying consolidated balance sheet.

At September 30, 2025, the Company had foreign currency contracts in the form of forward exchange contracts with notional amounts of approximately USD $60 million which all have maturities of less than one year.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

**7.** **<u>Leases:</u>**

The Company leases its offices and warehouses, vehicles, and certain office equipment, substantially all of which are classified as operating leases. The Company currently has no material financing leases. The Company determines if an arrangement is a lease at inception. Operating lease assets and obligations are recognized at the lease commencement date based on the present value of lease payments over the lease term.

In determining lease asset value, the Company considers fixed or variable payment terms, prepayments, incentives, and options to extend or terminate, depending on the lease. Renewal, termination or purchase options affect the lease term used for determining lease asset value only if the option is reasonably certain to be exercised. The Company generally uses its incremental borrowing rate based on information available at the lease commencement date for the location in which the lease is held in determining the present value of lease payments.

As of September 30, 2025, the weighted average remaining lease term was 3.6 years and the weighted average discount rate used to determine the operating lease liability was 3.1%. Rental expense related to operating leases was $1.8 million and $5.1 million for the three and ninemonths ended September 30, 2025, respectively, as compared to $1.6 million and $4.9 million for the corresponding periods of the prior year. Operating lease payments included in operating cash flows totaled $5.0 million and $4.4 million for the nine months ended September 30, 2025 and 2024, respectively, and noncash additions to operating lease assets totaled $0.2 million and $1.2 million for the nine months ended September 30, 2025 and 2024, respectively.

**8.** **<u>Share-Based Payments:</u>**

The Company maintains a stock option program for key employees, executives and directors. The plans, all of which have been approved by shareholder vote, provide for the granting of both nonqualified and incentive options. Options granted under the plans typically have a six-year term and vest over a four to five-year period. The fair value of shares vested during the nine months ended September 30, 2025 and 2024 aggregated $0.02 million and $0.04 million, respectively. Compensation cost, net of estimated forfeitures, is recognized on a straight-line basis over the requisite service period for the entire award. Forfeitures are estimated based on historic trends. It is generally our policy to issue new shares upon exercise of stock options.

The following table sets forth information with respect to nonvested options for the nine months ended September 30, 2025:

---

| | | |
|:---|:---|:---|
|  | **Number of Shares** | **Weighted Average Grant-Date Fair Value** |
| Nonvested options at January 1, 2025 | 118650 | $30.02 |
| Nonvested options granted |  |  |
| Nonvested options vested or forfeited | (8000) | $23.90 |
| Nonvested options at September 30, 2025 | 110650 | $30.46 |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

Share-based payment expense decreased income before income taxes by $0.37 million and $1.31 million for the three and nine months ended September 30, 2025 respectively, as compared to decreases of $0.60 million and $1.77 million for the three and nine months ended September 30, 2024 respectively, and decreased income attributable to Interparfums, Inc. by $0.26 million and $0.87 million for the three and nine months ended September 30, 2025 respectively, as compared to $0.4 million and $1.17 million for the corresponding periods of the prior year .

The following table summarizes stock option information as of September 30, 2025:

---

| | | |
|:---|:---|:---|
|  | **Shares** | **Weighted Average<br> Exercise Price** |
| Outstanding at January 1, 2025 | 248430 | $103.00 |
| Options forfeited | (7100) | 121.22 |
| Options exercised | (27430) | 76.98 |
| Outstanding at September 30, 2025 | 213900 | $105.73 |
| Options exercisable | 103250 | $82.55 |
| Options available for future grants | 499495 |  |

---

As of September 30, 2025, the weighted average remaining contractual life of options outstanding is 2.8 years (1.0 years for options exercisable); the aggregate intrinsic value of options outstanding and options exercisable is $2.1 million and $2.1 million, respectively; and unrecognized compensation cost related to stock options outstanding aggregated $2.7 million.

Cash proceeds, tax benefits and intrinsic value related to stock options exercised during the nine months ended September 30, 2025 and 2024 were as follows:

---

| | | |
|:---|:---|:---|
| (In thousands) | **September 30, 2025** | **September 30, 2024** |
| Cash proceeds from stock options exercised | $2112 | $1729 |
| Tax benefits | 205 | 272 |
| Intrinsic value of stock options exercised | 1618 | 1721 |

---

There were no options granted during the nine months ended September 30, 2025 and September 30, 2024.

Expected volatility is estimated based on the historic volatility of the Company's common stock. The expected term of the option is estimated based on historical data. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of the grant of the option and the dividend yield reflects the assumption that the dividend payout as authorized by the Board of Directors maintain its current payout ratio as a percentage of earnings.

In March 2022, Interparfums SA, our 72% owned French subsidiary, approved a plan to grant an aggregate of 88,400 shares of its stock to all Interparfums SA employees and corporate officers having more than six months of employment at grant date, subject to certain corporate performance conditions. The corporate performance conditions were met and therefore in June 2025,106,046 shares, adjusted for stock splits, were distributed.

The fair value of the grant had been determined based on the quoted stock price of Interparfums SA shares as reported by the Euronext on the date of grant. The aggregate cost of the grant of approximately $4.2 million was recognized as compensation cost on a straight-line basis over the requisite three and a quarter year service period.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

In order to avoid dilution of the Company's ownership of Interparfums SA, all shares distributed pursuant to this plan were pre-existing shares of Interparfums SA, purchased in the open market by Interparfums SA. As of September 30, 2025 the Company acquired 106,046 shares at an aggregate cost of $4.5 million.

All share purchases and issuances have been classified as equity transactions on the accompanying balance sheet.

**9.** **<u>Net Income Attributable to Interparfums, Inc. Common Shareholders:</u>**

Net income attributable to Interparfums, Inc. per common share ("basic EPS") is computed by dividing net income attributable to Interparfums, Inc. by the weighted average number of shares outstanding. Net income attributable to Interparfums, Inc. per share assuming dilution ("diluted EPS"), is computed using the weighted average number of shares outstanding, plus the incremental shares outstanding assuming the exercise of dilutive stock options using the treasury stock method.

The reconciliation between the numerators and denominators of the basic and diluted EPS computations is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **Nine Months Ended** | **Nine Months Ended** |
| (In thousands) | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Numerator: |  |  |  |  |
| &nbsp;&nbsp;Net income attributable to Interparfums, Inc. | $65809 | $62259 | $140289 | $140130 |
| Denominator: |  |  |  |  |
| &nbsp;&nbsp;Weighted average shares | 32113 | 32026 | 32114 | 32030 |
| &nbsp;&nbsp;Effect of dilutive securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock options | 36 | 240 | 44 | 236 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Denominator for diluted earnings per share | 32149 | 32266 | 32158 | 32266 |
| Earnings per share: |  |  |  |  |
| &nbsp;&nbsp;Net income attributable to |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interparfums, Inc. common shareholders: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $2.05 | $1.94 | $4.37 | $4.37 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $2.05 | $1.93 | $4.36 | $4.34 |

---

Not included in the above computations are the effect of antidilutive potential common shares which consist of outstanding options to purchase 0.09 million shares of common stock for the three and nine months ended September 30, 2025 and 0.05 million shares of common stock for the three and nine months ended September 30, 2024.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

**10.** **<u>Segment and Geographic Areas:</u>**

The Company manufactures and distributes one product line, fragrances and fragrance related products. The Company manages its business in two segments, European based operations and United States based operations. The European based operations, assets and business operations are primarily conducted in France, and include the results and assets of Interparfums Luxury Brands, Inc., located in the United States. For United States based operations, assets and business operations are primarily conducted in the United States, and include the results and assets of Interparfums Italia Srl, located in Italy. Both European based operations and United States based operations primarily represent the sale of prestige brand name fragrances.

Information on the Company's operations by segments is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2025** |
|  | **United States<br> based operations** | **European<br> based operations** | **Total** | **United States<br> based operations** | **European<br> based operations** | **Total** |
| Net sales | $137158 | $295226 | $432384 | $327262 | $783601 | $1110863 |
| Eliminations (a) |  | (2805) | (2805) |  | (8529) | (8529) |
|  | 137158 | 292421 | 429579 | 327262 | 775072 | 1102334 |
| Less: (b) |  |  |  |  |  |  |
| Cost of sales | 57448 | 100426 |  | 134020 | 261951 |  |
| Eliminations (a) |  | (1112) |  |  | (3520) |  |
| Segment gross margin | 79710 | 193107 | 272817 | 193242 | 516641 | 709883 |
| Less: (b) |  |  |  |  |  |  |
| Advertising and Promotion | 21458 | 44054 |  | 52748 | 133133 |  |
| Employee related costs | 12506 | 17512 |  | 39721 | 54175 |  |
| Royalties | 10286 | 24432 |  | 24559 | 65925 |  |
| Other segment items (c) | 10201 | 23812 |  | 28349 | 68464 |  |
| Segment income from operations | $25259 | $83297 | $108556 | $47865 | $194944 | $242809 |
| *Reconciliation:* |  |  |  |  |  |  |
| Interest expense |  |  | 2305 |  |  | 5637 |
| Loss on foreign currency |  |  | 2215 |  |  | 4576 |
| Interest and investment income |  |  | (2547) |  |  | (1199) |
| Other income |  |  | (978) |  |  | (1302) |
| Income before income taxes |  |  | $107561 |  |  | $235097 |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** |
|  | **United States<br> based operations** | **European<br> based operations** | **Total** | **United States<br> based operations** | **European<br> based operations** | **Total** |
| Net sales | $146101 | $282481 | $428582 | $362059 | $739454 | $1101513 |
| Eliminations (a) |  | (3953) | (3953) |  | (10692) | (10692) |
|  | 146101 | 278528 | 424629 | 362059 | 728762 | 1090821 |
| Less: (b) |  |  |  |  |  |  |
| Cost of sales | 59632 | 95462 |  | 151465 | 249279 |  |
| Eliminations (a) |  | (1625) |  |  | (4225) |  |
| Segment gross margin | 86469 | 184691 | 271160 | 210594 | 483708 | 694302 |
| Less: (b) |  |  |  |  |  |  |
| Advertising and Promotion | 23416 | 43414 |  | 55312 | 126230 |  |
| Employee related costs | 12752 | 18206 |  | 38090 | 52934 |  |
| Royalties | 10686 | 23334 |  | 26181 | 62052 |  |
| Other segment items (c) | 10114 | 23244 |  | 29272 | 65435 |  |
| Segment income from operations | $29501 | $76493 | $105994 | $61739 | $177057 | $238796 |
| *Reconciliation:* |  |  |  |  |  |  |
| Interest expense |  |  | 1978 |  |  | 5726 |
| Loss on foreign currency |  |  | 3355 |  |  | 3085 |
| Interest and investment loss (income) |  |  | 254 |  |  | (1690) |
| Other expense (income) |  |  | 1 |  |  | (35) |
| Income before income taxes |  |  | $100406 |  |  | $231710 |

---

(a) Eliminations of intercompany sales relate to European based operations products sold to United States based operations.

(b) The significant expense categories and amounts align with the segment-level information that is regularly provided to the chief operating decision maker.

(c) Other segment items for each reportable segment include expenses for professional services, travel and entertainment, rent, warehousing, shipping, depreciation and amortization, and other selling, general and administrative costs.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

Other segment disclosures:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net income attributable to Interparfums, Inc.: |  |  |  |  |
| United States | $20822 | $24263 | $39045 | $49015 |
| Europe | 46257 | 39869 | 105001 | 95966 |
| Eliminations | (1270) | (1873) | (3757) | (4851) |
|  | $65809 | $62259 | $140289 | $140130 |
| Depreciation and amortization expense: |  |  |  |  |
| United States | $1736 | $1701 | $5169 | $5128 |
| Europe | 4809 | 4480 | 13667 | 13073 |
|  | $6545 | $6181 | $18836 | $18201 |
| Interest and investment (income) loss: |  |  |  |  |
| United States | $(1048) | $2 | $(1788) | $(2) |
| Europe | (1499) | 252 | 589 | (2376) |
| Eliminations |  |  |  | 688 |
|  | $(2547) | $254 | $(1199) | $(1690) |
| Interest expense: |  |  |  |  |
| United States | $489 | $195 | $1093 | $1350 |
| Europe | 1816 | 1783 | 4544 | 5064 |
| Eliminations |  |  |  | (688) |
|  | $2305 | $1978 | $5637 | $5726 |
| Income tax expense: |  |  |  |  |
| United States | $5271 | $5617 | $8796 | $11215 |
| Europe | 19132 | 18120 | 46684 | 44384 |
| Eliminations | (121) | (166) | (262) | (625) |
|  | $24282 | $23571 | $55218 | $54974 |
| Additions to long-lived assets(a): |  |  |  |  |
| United States | $166 | $171 | $708 | $1109 |
| Europe | 5099 | 874 | 45040 | 2630 |
|  | $5265 | $1045 | $45748 | $3739 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) Total long-lived assets include property, equipment and leasehold improvements, trademarks, licenses, and other intangible assets, and right-of-use assets.

---

| | | |
|:---|:---|:---|
|  | **September 30,** | **December 31,** |
|  | **2025** | **2024** |
| Total Assets: |  |  |
| &nbsp;&nbsp;&nbsp;United States | $381871 | $352139 |
| &nbsp;&nbsp;&nbsp;Europe | 1199593 | 1073326 |
| &nbsp;&nbsp;&nbsp;Eliminations | (16814) | (14204) |
|  | $1564650 | $1411261 |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

---

| | |
|:---|:---|
| **I** **tem** **2** **:** | [**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**](#TOC) |

---

**Forward Looking Information**

Statements in this report which are not historical in nature are forward-looking statements. Although we believe that our plans, intentions and expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such plans, intentions or expectations will be achieved. In some cases, you can identify forward-looking statements by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will" and "would" or similar words. You should not rely on forward-looking statements because actual events or results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to, the risks and uncertainties discussed under the headings "Forward Looking Statements" and "Risk Factors" in Interparfums' annual report on Form 10-K for the fiscal year ended December 31, 2024, and the reports Interparfums files from time to time with the Securities and Exchange Commission ("SEC"). Interparfums does not intend to and undertakes no duty to update the information contained in this report.

**Overview**

We operate in the fragrance business, and manufacture, market and distribute a wide array of prestige fragrances and fragrance related products. We manage our business in two segments, European based operations and United States based operations. Certain prestige fragrance products are produced and marketed by our European based operations through our 72% owned subsidiary in Paris, Interparfums SA, which is also a publicly traded company as 28% of Interparfums SA shares trade on the Euronext.

We produce and distribute fragrance products through our European based operations primarily under license agreements with brand owners, and European based fragrance product sales represented approximately 70% and 67% of net sales for the nine months ended September 30, 2025 and 2024, respectively. We have built a portfolio of prestige brands, which include Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas, Solférino and Van Cleef & Arpels, whose products are distributed in over 120 countries around the world.

Through our United States based operations, we also produce and distribute fragrance and fragrance related products. United States based operations represented 30% and 33% of net sales for the nine months ended September 30, 2025 and 2024, respectively. These fragrance products are sold primarily pursuant to license or other agreements with the owners of the Abercrombie & Fitch, Anna Sui, Donna Karan/DKNY, Emanuel Ungaro, Ferragamo, Graff, GUESS, Hollister, MCM, Oscar de la Renta and Roberto Cavalli brands.

Substantially all of our prestige fragrance brands are licensed from unaffiliated third parties, and our business is dependent upon the continuation and renewal of such licenses. With respect to the Company's largest brands, we license the Jimmy Choo, Coach, Montblanc, GUESS, Lacoste, Donna Karan/DKNY, and Ferragamo brand names.

As a percentage of net sales for the nine months ended September 30, 2025 and 2024, product sales for the Company's largest brands represented 78% and 75%, respectively, with a split by brand as follows:

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended**<br> **September 30,** | **Nine Months Ended**<br> **September 30,** |
|  | **2025** | **2024** |
| Jimmy Choo | 18% | 17% |
| Coach | 16% | 14% |
| Montblanc | 15% | 16% |
| GUESS | 11% | 11% |
| Lacoste | 8% | 6% |
| Donna Karan/DKNY | 6% | 7% |
| Ferragamo | 4% | 4% |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

Quarterly sales fluctuations are influenced by the timing of new product launches as well as the third and fourth quarter holiday season. In certain markets where we sell directly to retailers, seasonality is more evident. We primarily sell directly to retailers in France, the United States, and Italy.

We grow our business in two distinct ways. First, we grow by adding new brands to our portfolio, through new licenses or other arrangements, or outright acquisitions of brands. Second, we grow through the introduction of new products and by supporting new and established products through advertising, merchandising and sampling, as well as phasing out underperforming products, so we can devote greater resources to those products with greater potential. The economics of developing, producing, launching and supporting products influence our sales and operating performance each year. The introduction of new products may have some cannibalizing effect on sales of existing products, which we take into account in our business planning.

Our business is not capital intensive, and it is important to note that we do not own manufacturing facilities. We act as a general contractor and source our needed components from our suppliers. These components are received and stored directly at our third party fillers or received at one of our distribution centers. For those components received at one of our distribution centers, based upon production needs, the components are subsequently sent to one of several third party fillers, which manufacture the finished product for us and then deliver them to one of our distribution centers.

As with any global business, many aspects of our operations are subject to influences outside our control. We believe we have a strong and well diversified brand portfolio with global reach and potential. As part of our strategy, we plan to continue to make investments behind fast-growing markets and channels to grow market share.

Our reported net sales are impacted by changes in foreign currency exchange rates as approximately 50% of net sales of our European based operations are denominated in U.S. dollars, while almost all costs of our European based operations are incurred in euro. We address certain financial exposures through a controlled program of risk management that includes the use of derivative financial instruments and primarily enter into foreign currency forward exchange contracts to reduce the effects of fluctuating foreign currency exchange rates.

**Recent Important Events**

Please see our discussion of Recent Important Events, which is incorporated by reference to Note 2 to the Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

**Discussion of Critical Accounting Policies**

Information regarding our critical accounting policies can be found in our 2024 Annual Report on Form 10-K filed with the SEC.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Results of Operations**

***Three and Nine Months Ended September 30, 2025 as Compared to the Three and Nine Months Ended September 30, 2024***

**Net Sales:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
| (in millions) | **2025** | **2024** | **% Change** | **2025** | **2024** | **% Change** |
| European based product sales | $295.3 | $282.4 | 5% | $783.6 | $739.4 | 6% |
| United States based product sales | 137.1 | 146.1 | (6)% | 327.2 | 362.1 | 10% |
| Eliminations | (2.8) | (3.9) | n/a | (8.5) | (10.7) | n/a |
|  | $429.6 | $424.6 | 1% | $1102.3 | $1090.8 | 1% |

---

\*n/a = not applicable

Net sales for the three months ended September 30, 2025 increased 1% from the three months ended September 30, 2024. The average dollar/euro exchange rate for the current third quarter was 1.17 compared to 1.10 in the third quarter of 2024, resulting in a positive foreign exchange impact on net sales of 2.2% in the three months ended September 30, 2025 as compared to the prior year period. Net sales for the nine months ended September 30, 2025 also increased 1% as compared to the nine months ended September 30, 2024. The average dollar/euro exchange rate for the nine months ended September 30, 2025 was 1.12 compared to 1.09 for the nine months ended September 30 2024, resulting in a positive foreign exchange impact on nets sales of 1.1% as compared to the prior year period. The discontinuation of the Dunhill license decreased net sales for the nine months ended September 30, 2025 1% compared to the prior year period and a moderate impact in the current quarter compared to the prior year period. Overall organic growth on a year to date basis is 1.2% compared to the prior year period as consumers are being more selective and retailers are taking a cautious approach to inventory.

For European based operations, sales in the three months ended September 30, 2025 increased 5%, compared to the corresponding period of the prior year, driven by Jimmy Choo, Lacoste and Coach, which grew by 16%, 8% and 6%, respectively. These increases were driven by continued strong performance in these brands' established lines. Sales of Montblanc were down 2% in the third quarter, despite the recent release of the Montblanc *Explorer Extreme*, resulting in a 6% decline for the nine months ended September 30, 2025, as compared to the prior year period. We have further enhanced the brand with the launch of Montblanc *Signature Elixir* and believe it will gain traction through the balance of the year and into 2026.

For United States based operations, sales in the three months ended September 30, 2025 decreased 6% compared to the corresponding period of the prior year as a result of the discontinuation of the Dunhill license. With the phase-out of Dunhill fragrances completed in August of 2024, we expect minimal impact on a quarter-over-quarter comparison going forward. GUESS fragrance sales declined moderately by 3% in the three months ended September 30, 2025, compared to the corresponding period of the prior year, due to a high base in the prior period third quarter and the phasing of innovation. The brand continues to perform well, and we believe the brand is poised for sales growth in the final quarter of the year. Donna Karan/DKNY fragrance sales declined 14% in the three months ended September 30, 2025, compared to the corresponding period of the prior year, due to robust growth levels achieved last year. Based on planned shipments through year end and the brand's popularity during the holiday season, particularly in the Americas, we believe the brand will grow in the final quarter of the year. Roberto Cavalli fragrance sales continue to benefit from increased focus, investment and innovation, growing 44% and 33% in the three and nine months ended September 30, 2025, respectively, compared to the corresponding periods in the prior year. The brand continues to benefit from strong innovation, including the blockbuster launch of Roberto Cavalli *Serpentine* and a new duo, Just Cavalli *Give Me Magic*. MCM sales rose by 6% in the third quarter of 2025 compared to the third quarter of 2024 with the continued success from the launch of the *MCM Collection*. For the nine months ended September 30, 2025, United States based operations sales decreased 10% on a reported basis and 6% on an organic basis, compared to the corresponding period of the prior year.

While the 2025 third quarter saw only a slight overall increase, we are encouraged by our agility and pricing actions that are underway and expect to see the full impact of our efforts throughout the remainder of 2025 and through 2026. We continue to focus on our long-term strategy, innovative product development, and high service levels for our global retail and distribution partners. While the pace of growth in the fragrance market is starting to slow down, the power of our diverse brand portfolio, in combination with our agile operating model, should help us gain market share.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

---

| | | |
|:---|:---|:---|
| ***Net Sales to Customers by Region*** | **Nine Months Ended** | **Nine Months Ended** |
|  ***(In millions)*** | **September 30,** | **September 30,** |
|  | **2025** | **2024** |
| North America | $414.8 | $397.4 |
| Western Europe | 288.5 | 281.0 |
| Asia/Pacific | 140.8 | 154.2 |
| Central and South America | 99.6 | 88.9 |
| Eastern Europe | 81.1 | 76.8 |
| Middle East and Africa | 77.5 | 92.5 |
|  | $1102.3 | $1090.8 |

---

In the nine months ended September 30, 2025, net sales in our largest market, North America, rose 4% as compared to the prior year period, followed by an increase in Western Europe of 3%. Our sales in Asia/Pacific decreased by 9% driven by distribution disruptions in South Korea and India in the current year. Our net sales in Eastern Europe were also robust, up 6% in the nine months ended September 30, 2025 as compared to the prior year period when we faced temporary sourcing constraints. Central and South America net sales increased 12%. Middle East and Africa net sales declined 16% primarily related to a disproportionate impact from the exit of the Dunhill license due to its significant presence. Excluding the impact of Dunhill, Middle East and Africa net sales declined 7% due to the impacts of the conflicts in the region and a reduction in the number of doors in many markets that are now more focused on higher-end luxury fragrances.

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***Gross Profit Margin*** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(in millions) | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **European based operations** |  |  |  |  |
| Net sales | $295.3 | $282.4 | $783.6 | $739.4 |
| Cost of sales | 100.5 | 95.5 | 262.0 | 249.3 |
| Gross profit margin | $194.8 | $186.9 | $521.6 | $490.1 |
| Gross profit margin as a percentage of net sales | 66.0% | 66.2% | 66.6% | 66.3% |
| **United States based operations**  |  |  |  |  |
| Net sales | $137.1 | $146.1 | $327.2 | $362.1 |
| Cost of sales | 57.4 | 59.6 | 134.0 | 151.4 |
| Gross profit margin | $79.7 | $86.5 | $193.2 | $210.7 |
| Gross profit margin as a percentage of net sales | 58.1% | 59.2% | 59.0% | 58.2% |

---

The Company's gross profit margin as a percentage of net sales was 63.5% and 64.4% for the three and nine months ended September 30, 2025 as compared to 63.9% and 63.6% for the corresponding periods of the prior year. The Company continued to benefit from favorable segment, brand, and channel mix, in the nine months ended September 30, 2025 as compared to the prior year period. However, during the three months ended September 30, 2025 as compared to the prior year period, these favorable tailwinds as well as additional pricing actions that were taken at the back end of the quarter were not sufficient to offset the impacts of higher tariffs on our US imports, which represented $6 million.

For European based operations, gross profit margin as a percentage of net sales was 66.0% and 66.6% for the three and nine months ended September 30, 2025, respectively, as compared to 66.2% and 66.3% for the corresponding period of the prior year. European based operations were negatively impacted by tariffs during the three months ended September 30, 2025 as compared to the prior year period, offset by pricing increases in the United States and brand and channel mix. During the nine months ended September 30, 2025, favorable channel mix resulted in the increase in gross profit as percentage of sales compared to the prior year period.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

For United States based operations, gross profit margin as a percentage of net sales was at 58.1% and 59.0% for the three and nine months ended September 30, 2025 respectively, as compared to 59.2% and 58.2% for the corresponding periods of the prior year. United States based operations saw a moderate decline due to the negative impact of tariffs as well as brand and channel mix in the three months ended September 30, 2025. The increase in the nine months ended September 30, 2025 was mainly driven by the discontinuation of Dunhill products, which were sold at lower margins in 2024 as is customary during sell-off periods.

Generally, we do not bill customers for shipping and handling costs, which are included in selling, general and administrative expenses in the consolidated statements of income. As such, our Company's gross profit may not be comparable to other companies, which may include these expenses as a component of cost of goods sold.

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***Selling, general and administrative expenses*** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  ***(In millions)*** | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **European based operations**  |  |  |  |  |
| Selling, general and administrative expenses | $109.8 | $108.1 | $321.7 | $306.6 |
| Selling, general and administrative expenses as a percentage of net sales | 37.2% | 38.3% | 41.1% | 41.5% |
| **United States based operations** |  |  |  |  |
| Selling, general and administrative expenses | $54.5 | $57.0 | $145.4 | $148.9 |
| Selling, general and administrative expenses as a percentage of net sales | 39.7% | 39.0% | 44.4% | 41.1% |

---

The Company's selling, general and administrative expenses as a percentage of net sales were 38.2% and 42.4% for the three and nine months ended September 30, 2025 as compared to38.9% and41.8% for the three and nine months ended September 30, 2024. The decrease in the quarter was driven by the phasing of promotional and advertising activities. The increase in the first three quarters of the year was largely driven by increased overall spending on promotional and advertising activities and increased employee related costs, as well as negative foreign exchange impacts.

For European based operations, selling, general and administrative expenses increased 1.5% and 4.9% for the three and nine months ended September 30, 2025, respectively as compared to the corresponding periods of the prior year, and represented 37.2% and 41.1% of net sales for the three and nine months ended September 30, 2025, as compared to 38.3% and 41.5% for the three and nine months ended September 30, 2024. A significant portion of our expense in European based operations are denominated in euros, resulting in costs as reported in USD. The decrease in selling, general and administrative expenses as a percentage of net sales in the third quarter and first nine months of the year was driven by the expiration of the 2022 free-share plan and distribution of shares in France in the second quarter resulting in the decrease in stock compensation amortization. For United States based operations, selling, general and administrative expenses decreased 4.4% and 2.3% for the three and nine months ended September 30, 2025 as compared to the corresponding periods of the prior year, and represented 39.7% and 44.4% of net sales for the three and nine months ended September 30, 2025, as compared to 39.0% and 41.1% for the three and nine months ended September 30, 2024. The increase in selling, general and administrative expenses as a percentage of net sales was largely driven by lower sales in 2025 with the discontinuation of Dunhill in 2024.

Promotion and advertising included in selling, general and administrative expenses aggregated $65.5 million and $185.9 million for the three and nine months ended September 30, 2025, respectively, as compared to $66.8 million and $181.5 million for the corresponding periods of the prior year and represented 15.3% and 16.9% of net sales for the three and nine months ended September 30, 2025, respectively, as compared to15.7% and16.6% for the corresponding periods of the prior year. Promotion and advertising are integral parts of our industry, and we continue to invest heavily to support new product launches and to build brand awareness. We are also investing in line with anticipated sell out by our retailers, which we believe are higher than our reported sales. We believe that our promotion and advertising efforts have a beneficial effect on sales. As such, the Company is focused on increasing promotional and advertising spending to support the continued success of our brands. Long term, we continue to anticipate that on a full year basis, promotion and advertising expenditures will aggregate approximately 21% of net sales.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

Royalty expense included in selling, general and administrative expenses aggregated $34.7 million and $90.5 million for the three and nine months ended September 30, 2025, respectively, as compared to $34.0 million and $88.2 million for the corresponding periods of the prior year. Royalty expense represented 8.1% and 8.2% of net sales for both the three and nine months ended September 30, 2025 as compared to8.0% and 8.1% of net sales for the corresponding periods of the prior year. This increase was primarily driven by unfavorable brand mix.

***Income from Operations***

As a result of the above analysis regarding net sales, gross profit margins and selling, general and administrative expenses, our operating margins aggregated 25.3% and 22.0% for the three and nine months ended September 30, 2025, respectively, as compared to25.0% and21.9% for the corresponding period of the prior year.

***Other Income and Expense***

Overall, other income and expense for the nine months ended September 30, 2025, was a loss of $7.7 million as compared to a loss of $7.1 million in the corresponding prior year period. One of the main drivers is the impact of our gains and losses on foreign currency where we recognized a loss of $4.6 million in the first nine months of 2025 compared to $3.1 million in the first nine months of 2024. Another driver of this change is the impact of our gains and losses on marketable securities where we recorded a loss of $2.5 million in the first nine months of 2025 and a loss of $0.8 million in the first nine months of 2024. Changes in interest expense and interest income were favorable year-over-year with net interest expense of $1.8 million during the nine months ended September 30, 2025 as compared to a net interest expense of $2.9 million in the prior year period.

Interest expense is primarily related to the financing of brand and licensing acquisitions, as well as our headquarters in Paris. Long-term debt including current maturities aggregated $196.9 million and $157.3 million as of September 30, 2025 and December 31, 2024, respectively. Interest expense was $5.1 million in the nine months ended September 30, 2025 compared to $5.3 million in the prior year period.

We enter into foreign currency forward exchange contracts to manage exposure related to receivables from unaffiliated third parties denominated in a foreign currency and occasionally to manage risks related to future sales expected to be denominated in a foreign currency. Approximately 50% of net sales of our European based operations are denominated in U.S. dollars. Gains and losses in derivatives designated as hedges are accumulated in other comprehensive income and gains and losses in derivatives not designated as hedges are included in (gain) loss on foreign currency on the accompanying consolidated income statements. Such gains and losses were immaterial in the three and nine months ended September 30, 2025 and 2024.

Interest and investment income represents interest earned on cash and cash equivalents and short-term investments and realized and unrealized gains and losses on marketable equity securities. Interest income was $4.4 million in the nine months ended September 30, 2025 compared to $2.7 million in the prior year period.

***Income Taxes***

Our consolidated effective tax rate was 23.5% and 23.7% for the nine months ended September 30, 2025 and 2024, respectively. The effective tax rate for European based operations was 24.4% and 25.0% for the nine months ended September 30, 2025 and 2024, respectively. The decrease in taxes resulted from a $3 million favorable outcome to our mutual agreement procedure between the French and United States tax authorities in which we were able to reclaim the tax assessment paid in France in 2023. The gain was offset by a $1 million one-time tax assessment included in the tax expense as a result of a tax audit conducted for the 2022 and 2023 tax years. The effective tax rate for United States based operations was 20.0% for the nine months ended September 30, 2025, as compared to 19.8% for the corresponding period of the prior year. Our effective tax rate for United States based operations differs from the 21% statutory rate in the United States as it is a blended rate across multiple jurisdictions, and takes into account benefits received from the exercise of stock options as well as deductions we are allowed for a portion of our foreign derived intangible income, slightly offset by state and local taxes. Other than as discussed above, we did not experience any significant changes in tax rates, and none were expected in jurisdictions where we operate.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

***Net Income***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(In thousands) | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net income attributable to European based operations | $63726 | $54445 | $144590 | $132572 |
| Net income attributable to United States based operations | 20823 | 24263 | 39046 | 49015 |
| Eliminations | (1270) | (1873) | (3757) | (4851) |
| Net income | 83279 | 76835 | 179879 | 176736 |
| Less: Net income attributable to the noncontrolling interest | 17470 | 14576 | 39590 | 36606 |
| Net income attributable to Interparfums, Inc. | $65809 | $62259 | $140289 | $140130 |

---

Net income attributable to Interparfums, Inc. was $65.8 million and $140.3 million for the three and nine months ended September 30, 2025, respectively, as compared to $62.3 million and $140.1 million for the corresponding period of the prior year.

Net income attributable to European based operations was $63.7 million and $144.6 million for the three and nine months ended September 30, 2025, as compared to $54.4 million and $132.6 million for the corresponding periods of the prior year, while net income attributable to United States based operations was $20.8 million and $39.0 million the three and nine months ended September 30, 2025, as compared to $24.3 million and $49.0 million the corresponding periods of the prior year. The significant fluctuations in net income for both European based operations and United States based operations are directly related to the previous discussions pertaining to changes in sales, gross margin, and selling, general and administrative expenses.

The noncontrolling interest arises from our 72% owned subsidiary in Paris, Interparfums SA, which is also a publicly traded company, as 28% of Interparfums SA shares trade on the Euronext. Net income attributable to the noncontrolling interest is directly related to the profitability of our European based operations and aggregated 28% of European based operations net income for both the nine months ended September 30, 2025 and 2024. Net profit margins attributable to Interparfums, Inc. for the nine months ended September 30, 2025 and 2024 aggregated 12.7% and 12.8%, respectively.

**Liquidity and Capital Resources**

Our conservative financial tradition has enabled us to amass significant cash balances. As of September 30, 2025, we had $187.9 million in cash, cash equivalents and short-term investments, the majority of which are held in euros by our European based operations and is readily convertible into U.S. dollars. We have not experienced any liquidity issues to date, and do not expect any liquidity issues relating to such cash and cash equivalents and short-term investments.

As of September 30, 2025, working capital aggregated $688.0 million. Approximately 77% of the Company's total assets are held by European based operations, and approximately $294.4 million of trademarks, licenses and other intangible assets are also held by European based operations.

The Company is party to a number of licenses and other agreements for the use of trademarks and rights in connection with the manufacture and sale of its products expiring at various dates through 2039. In connection with most of these license agreements, the Company is subject to minimum annual advertising commitments, minimum annual royalties and other commitments. See Item 8. Financial Statements and Supplementary Data – Note 11 – Commitments in our 2024 annual report on Form 10-K, which is incorporated by reference herein. Future advertising commitments are estimated based on planned future sales for the license terms that were in effect at December 31, 2024, without consideration for potential renewal periods and do not reflect the fact that our distributors share our advertising obligations.

The Company hopes to continue to benefit from its strong financial position to potentially acquire one or more brands, either on a proprietary basis or as a licensee. In July 2025, our 72% owned French subsidiary, Interparfums SA, signed an exclusive fragrance license agreement with Longchamp running through December 31, 2036. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. The first launch is expected in 2027. In June 2025, our 72% owned French subsidiary, Interparfums SA, acquired all intellectual property rights relating to Maison Goutal held by Amorepacific Europe, which is operating the Goutal brand under an existing license agreement that expires on December 31, 2025, when Interparfums SA will begin commercial use of the fragrance brand. Additionally, in June 2025, we renewed the Coach license agreement for an additional five-year term, extending the license through June 30, 2031.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

In December 2024, our 72% owned French subsidiary, Interparfums SA, obtained all Off-White brand names and registered trademarks for Class 3 fragrance and cosmetics products, subject to an existing license that expires on December 31, 2025, when Interparfums SA will begin commercial use of the fragrance brands. Furthermore, in December 2024, we renewed the Van Cleef & Arpels license agreement for an additional nine-year term, beginning January 1, 2025. In July 2023, we entered into a global licensing agreement for the creation, development and distribution of fragrances and fragrance related products under the Roberto Cavalli brand. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. This license took effect in July 2023, and we began shipping products in February 2024.

In December 2022, we entered into a long-term global licensing agreement for the creation, development and distribution of fragrances and fragrance related products under the Lacoste brand. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. This license took effect, and products began shipping in January 2024.

Cash provided by operating activities aggregated $68.4 million for the nine months ended September 30, 2025 compared to $49.7 million for the nine months ended September 30, 2024. For the nine months ended September 30, 2025, working capital items used $133.9 million in cash from operating activities, as compared to $147.0 million in the 2024 period. From a cash flow perspective, accounts receivables are up 23% from year end 2024. The balance is reasonable based on third quarter 2025 sales levels and seasonality of the business. Days' sales outstanding increased to 89 days, up from 83 days in the corresponding period of the prior year, driven by changes in our channel mix. Despite the increase, we are still seeing strong collection activity and do not anticipate any issues with collections of accounts receivable. From a cash flow perspective, inventory levels as of September 30, 2025 decreased 5% from year end 2024 as we continue to drive inventory efficiencies. We are doing this by increasing conversion of raw materials into finished goods, resulting in finished goods making up 68% of our inventory levels at September 30, 2025 as compared to 63% at September 30, 2024.

Cash flows provided by investing activities in 2025 are comprised of the net effect of purchases and sales of short-term investments. These investments consist of certificates of deposit with maturities greater than six months, marketable equity securities and other contracts. At September 30, 2025, approximately $2.3 million of certificates of deposit contain penalties where we would forfeit a portion of the interest earned in the event of early withdrawal.

These proceeds were offset by the payment for capital expenditures during the year. In March 2025, the Company paid approximately $19.7 million for the purchase of the Goutal trademark. Additionally, during the second and third quarters the Company purchased approximately $18.2 million of additional property in Paris attached to its French headquarters.

Our business is not capital intensive as we do not own any manufacturing facilities. On a full year basis, we typically spend approximately $5 million on tools and molds, depending on our new product development calendar. Capital expenditures also include amounts for office fixtures, computer equipment, and industrial equipment needed at our distribution centers.

Cash flows used in financing activities in 2025 reflect issuances and repayments of debt to institutional lenders and payment of dividends to stockholders.

Our short-term financing requirements are expected to be met by available cash on hand at September 30, 2025, and by short-term credit lines provided by domestic and foreign banks. The principal credit facilities for 2025 consist of $70.0 million unsecured revolving lines of credit provided by a consortium of domestic commercial banks and approximately $9.4 million (€8 million) in credit lines provided by a consortium of international financial institutions. There was $9.4 million of short-term borrowings outstanding pursuant to these facilities as of September 30, 2025 and $9.0 million outstanding as of September 30, 2024.

In February 2024, the Board of Directors authorized an annual dividend of $3.00 per share. In February 2025, the Board of Directors further increased the annual dividend to $3.20 per share. The next quarterly cash dividend of $0.80 per share is payable on December 31, 2025, to shareholders of record on December 15, 2025.

We believe that funds provided by or used in operations can be supplemented by our present cash position and available credit facilities, so that they will provide us with sufficient resources to meet all present and reasonably foreseeable future operating needs.

Inflation rates in the United States and foreign countries in which we operate did not have a significant impact on operating results for the nine months ended September 30, 2025; however, we have already started to see the impacts of tariffs on our cost structure and have adjusted our pricing accordingly, as such, we anticipate potential inflationary impacts in the last quarter of 2025 and beyond as our suppliers potentially adjust their pricing as well.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

---

| | |
|:---|:---|
| **Item 3:** | [**QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**](#TOC) |

---

**General**

We address certain financial exposures through a controlled program of risk management that primarily consists of the use of derivative financial instruments. We primarily enter into foreign currency forward exchange contracts in order to reduce the effects of fluctuating foreign currency exchange rates. We do not engage in the trading of foreign currency forward exchange contracts or interest rate swaps.

**Foreign Exchange Risk Management** 

We periodically enter into foreign currency forward exchange contracts to hedge exposure related to receivables denominated in a foreign currency and to manage risks related to future sales expected to be denominated in a currency other than our functional currency. We enter into these exchange contracts for periods consistent with our identified exposures. The purpose of the hedging activities is to minimize the effect of foreign exchange rate movements on the receivables and cash flows of Interparfums SA, whose functional currency is the euro. All foreign currency contracts are denominated in currencies of major industrial countries and are with large financial institutions, which are rated as strong investment grade.

All derivative instruments are required to be reflected as either assets or liabilities in the balance sheet measured at fair value. Generally, increases or decreases in fair value of derivative instruments will be recognized as gains or losses in earnings in the period of change. If the derivative is designated and qualifies as a cash flow hedge, then the changes in fair value of the derivative instrument will be recorded in other comprehensive income.

Before entering into a derivative transaction for hedging purposes, we determine that the change in the value of the derivative will effectively offset the change in the fair value of the hedged item from a movement in foreign currency rates. Then, we measure the effectiveness of each hedge throughout the hedged period. Any hedge ineffectiveness is recognized in the income statement.

At September 30, 2025, we had foreign currency contracts in the form of forward exchange contracts of approximately USD $60 million with maturities of less than one year. We believe that our risk of loss as the result of nonperformance by any of such financial institutions is remote.

**Interest Rate Risk Management**

We mitigate interest rate risk by monitoring interest rates, and then determining whether fixed interest rates should be swapped for floating rate debt, or if floating rate debt should be swapped for fixed rate debt.

**Item 4.** [**CONTROLS AND PROCEDURES**](#TOC)

**Evaluation of Disclosure Controls and Procedures** 

Please see Item 9A. Controls and Procedures, "Evaluation of Disclosure Controls and Procedures" and "Remediation Plan," as contained in our 2024 annual report on Form 10-K as filed with the SEC ("2024 Annual Report"), which are incorporated by reference in this quarterly report. As stated in our 2024 Annual Report, we believe that the actions set forth under "Remediation Plan," will collectively remediate the material weaknesses identified. However, our material weaknesses will not be considered remediated until the controls operate for a sufficient period of time and management has concluded, through testing, that the related controls are operating effectively. We will continue to monitor the design and effectiveness of these and other processes, procedures, and controls and will make any further changes management deems appropriate. The above disclosure is applicable to the evaluation of our disclosure controls and procedures for this third quarter of 2025.

**Changes in Internal Control Over Financial Reporting** 

Except as described above, there has been no significant change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) that occurred during the quarterly period covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[**Part II. Other Information**](#TOC)

**[Item 1A. Risk Factors](#)**[.](#)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Information regarding our Risk Factors can be found in our 2024 Annual Report on Form 10-K filed with the SEC.

---

| | |
|:---|:---|
| **Item** **2.** | [**Unregistered Sales of Equity Securities and Use of Proceeds**.](#TOC) |

---

Item (c).

In February 2025, our Board of Directors authorized the Company to continue repurchasing up to 130,000 shares throughout 2025, which was increased to 260,000 shares in April 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| Interparfums, Inc. Purchase of Common Stock | Interparfums, Inc. Purchase of Common Stock | Interparfums, Inc. Purchase of Common Stock | Interparfums, Inc. Purchase of Common Stock | Interparfums, Inc. Purchase of Common Stock |
| Period | Total Number of Shares Purchased | Average price paid per share | Total number of shares purchased as part of publicly announced plans or programs | Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs |
| July 1-31 | 0 | n/a | 0 | 240,000 shares |
| August 1-31 | 0 | n/a | 0 | 240,000 shares |
| September 1-30 | 52872 | $102.67 | 52872 | 187,128 shares |
| Total | 52872 | n/a | 52872 | 187,128 shares |

---

[**Item 5. Other Information**](#TOC)

Item (c). During the third quarter of 2025, no director or officer has adopted or terminated either any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as such terms are defined in the applicable regulation.

Items 1. Legal Proceedings, 1A. Risk Factors, 3. Defaults Upon Senior Securities and 4. Mine Safety Disclosures, are omitted as they are either not applicable or have been included in Part I.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[**Item 6. Exhibits.**](#TOC)

The following documents are filed herewith:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Exhibit No. | &nbsp;&nbsp;Description | &nbsp;&nbsp;Page Number |
| &nbsp;&nbsp;[31.1](ex311_1.htm) | &nbsp;&nbsp;[Certifications required by Rule 13a-14(a) of Chief Executive Officer](ex311_1.htm) | &nbsp;&nbsp;29 |
| &nbsp;&nbsp;[31.2](ex312_2.htm) | &nbsp;&nbsp;[Certifications required by Rule 13a-14(a) of Chief Financial Officer and Principal Accounting Officer](ex312_2.htm) | &nbsp;&nbsp;30 |
| &nbsp;&nbsp;[32.1](ex321_3.htm) | &nbsp;&nbsp;[Certification required by Section 906 of the Sarbanes-Oxley Act of Chief Executive Officer](ex321_3.htm) | &nbsp;&nbsp;31 |
| &nbsp;&nbsp;[32.2](ex322_4.htm) | &nbsp;&nbsp;[Certification required by Section 906 of the Sarbanes-Oxley Act of Chief Financial Officer and Principal Accounting Officer](ex322_4.htm) | &nbsp;&nbsp;31 |
| &nbsp;&nbsp;101 | &nbsp;&nbsp;Interactive data files |  |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[**<u>SIGNATURES</u>**](#TOC)

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on the 5th day of November 2025.

---

| | |
|:---|:---|
|  | **INTERPARFUMS, INC.** |
| By: | /s/ Michel Atwood |
|  | Chief Financial Officer |

---

------

## Exhibit 31.1

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Exhibit 31.1**

**<u>CERTIFICATIONS</u>**

I, Jean Madar, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Interparfums, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based upon such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 5, 2025

---

| |
|:---|
| /s/ Jean Madar |
| Jean Madar, |
| Chief Executive Officer |

---

------

## Exhibit 31.2

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Exhibit 31.2**

I, Michel Atwood, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Interparfums, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based upon such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 5, 2025

---

| |
|:---|
| /s/ Michel Atwood |
| Michel Atwood |
| Chief Financial Officer and |
| Principal Accounting Officer |

---

------

## Exhibit 32.1

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Exhibit 32.1**

**CERTIFICATION**

The undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Interparfums, Inc., that the Quarterly Report of Interparfums, Inc. on Form 10-Q for the period ended September 30, 2025, fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operation of Interparfums, Inc.

---

| | | |
|:---|:---|:---|
| Date: November 5, 2025 | By: | /s/ Jean Madar |
|  |  | Jean Madar, |
|  |  | Chief Executive Officer |

---

A signed original of this written statement required by Section 906 has been provided to Interparfums, Inc. and will be retained by Interparfums, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

------

## Exhibit 32.2

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Exhibit 32.2**

**CERTIFICATION**

The undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Interparfums, Inc., that the Quarterly Report of Interparfums, Inc. on Form 10-Q for the period ended September 30, 2025, fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operation of Interparfums, Inc.

---

| | | |
|:---|:---|:---|
| Date: November 5, 2025 | By: | /s/ Michel Atwood |
|  |  | Michel Atwood |
|  |  | Chief Financial Officer and |
|  |  | Principal Accounting Officer |

---

A signed original of this written statement required by Section 906 has been provided to Interparfums, Inc. and will be retained by Interparfums, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.<br>

------